| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
BioHarvest Sciences Inc. Common Stock$3.1
+0.05 (+1.64%)
Market Cap
97.70 M
EPS
-0.61
P/E Ratio
-7.01 $
Value Trade
96.91 K
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
10.12 K
52 Week Range
4.10 - 12.80
% held by Insiders
16.12 %
% held by Institutions
9.82 %
Enterprise Value
91.32 M
Total Shares
17.33 M
Short %
0.49 %
Float Shares
14.92 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in BHST
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
BioHarvest Sciences Inc. Common Stock (BHST) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
BHST
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
BHST
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
BHST
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
BHST Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
BHST Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-BHST
Jun 18, 2026DATED JUNE 18, 2026 News Release dated
BioHarvest Sciences Inc. announced its participation in the 2026 BIO International Convention to showcase its proprietary Botanical Synthesis platform. Scheduled for June 24, the presentation aims to attract strategic partnerships to exploit the technology's potential in drug discovery and pharmaceutical applications. The company highlights its expansive capabilities and recent initiatives, focusing on the long-term value for its shareholders. However, challenges such as uncertain future contracts and market acceptance remain as significant considerations.
Read more →-BHST
May 14, 2026BioHarvest Sciences Reports First Quarter 2026 Financial Results
BioHarvest Sciences reported its first-quarter financial results for 2026, achieving an 8% increase in revenue year-over-year, totaling $8.5 million. Significant milestones were reached in the CDMO division, with a remarkable 135% growth in CDMO revenue. However, the company also reported an increased net loss of $2.6 million compared to $2.3 million from the previous year. The VINIA brand continues to thrive, boasting 90,000 active users and contributing significantly to the company's revenue.
Read more →-BHST
May 14, 2026Unaudited Interim Condensed Consolidated Financial Statements
BioHarvest Sciences Inc. released its unaudited interim consolidated financial statements for the three months ended March 31, 2026. The financial results show an increase in gross profit to $5,037 compared to $4,595 in the same quarter last year, although the net loss has risen to $2,641 from $2,338. Current liabilities have also increased, and the total assets declined from $47,665 to $45,558. The company continues developing its Botanical Synthesis technology, which aims to enhance production while minimizing negative environmental impacts.
Read more →-BHST
May 13, 2026BioHarvest Sciences Announces Successful Completion of Stage 1 Development of Saffron Composition for Nutraceutical and Culinary Applications
BioHarvest Sciences has successfully completed Stage 1 of its development for a saffron composition aimed at nutraceutical and culinary applications. This achievement marks a significant milestone in the company's efforts to innovate within these markets. The new composition is expected to provide enhanced benefits and broaden the scope of saffron use.
Read more →-BHST
May 13, 2026MATERIAL CHANGE REPORT DATED MAY 13, 2026 News Release dated
BioHarvest Sciences has announced the successful completion of Stage 1 in its saffron development program, establishing a stable saffron cell bank. This advancement triggers a move to Stage 2 of a multi-stage development agreement valued at $1.125 million, focusing on the production of saffron-derived ingredients for nutraceutical and culinary applications. BioHarvest holds a 25% ownership stake in the saffron composition being developed. The company believes its Botanical Synthesis platform can sustainably address the global saffron market's supply constraints.
Read more →-BHST
May 12, 2026BioHarvest Sciences Signs $1.2M CDMO Stage 2 Contract for the Development of a Rare Fragrance Using its Proprietary Botanical Synthesis Platform
BioHarvest Sciences has signed a $1.2 million Stage 2 contract with an unnamed UAE investment firm to develop a rare fragrance using its proprietary Botanical Synthesis technology. Following a successful Stage 1, the company aims to produce enough material for commercial trials within 6-9 months, setting the stage for entry into the $23 billion premium fragrance market by late 2027. With continued investment in manufacturing capacities, BioHarvest is positioned to establish long-term royalty-driven revenue streams.
Read more →-BHST
May 11, 2026MATERIAL CHANGE REPORT DATED MAY 11, 2026 Material Change Report dated
BioHarvest Sciences Inc. has announced a leadership transition, appointing Dr. Zaki Rakib as the new CEO, replacing Ilan Sobel who will now serve on the Board of Directors. This shift aims to streamline operations in both the direct-to-consumer and CDMO sectors. Dr. Rakib's extensive experience and prior leadership role are expected to further propel the company's growth. Under Sobel, the company grew from a pre-revenue phase to generating approximately $35 million in revenue in 2025.
Read more →-BHST
Apr 30, 2026DATED APRIL 30, 2026 News Release dated
BioHarvest Sciences Inc. announced it will report its first quarter 2026 financial results on May 14, 2026. A conference call and webcast will occur at 8:00 a.m. Eastern Time, aimed at discussing results and providing business updates. The company specializes in its Botanical Synthesis technology, which allows it to develop plant-based compounds without cultivating the actual plants. Attendees are encouraged to register for the webcast ahead of time, and a recorded replay will be available afterward.
Read more →-BHST
Apr 29, 2026DATED APRIL 29, 2026 News Release dated
BioHarvest Sciences has announced a significant leadership transition, appointing Dr. Zaki Rakib as the new CEO while transitioning Ilan Sobel to the Board of Directors. This move aims to strengthen the execution of the company's 'two-lens' strategy, which focuses on direct-to-consumer (D2C) growth and enhancing capabilities within its Contract Development and Manufacturing Organization (CDMO). Dr. Rakib's experience and leadership within the company are seen as pivotal for future growth, particularly in consolidating the company's operations. Sobel's prior success as CEO and continued board involvement is viewed as beneficial for expanding BioHarvest’s market presence.
Read more →-BHST
Mar 26, 2026BioHarvest Sciences Announces that VINIA is Now the No.1 Resveratrol Polyphenol Brand in the United States
BioHarvest Sciences has announced that its product VINIA has become the leading resveratrol polyphenol brand in the United States. This achievement highlights the brand's strong market presence and consumer preference. The company attributes this success to effective marketing strategies and the quality of its product.
Read more →-BHST
Mar 26, 2026DATED MARCH 26, 2026 News Release dated
BioHarvest Sciences Inc. announced that its VINIA brand has become the top Resveratrol Polyphenol Nutraceutical Brand in the U.S., reflecting its strong market presence and the success of the Botanical Synthesis platform. The product has shown clinically proven ability to enhance arterial dilation and blood flow, contributing to improved health outcomes. With over $30 million in U.S. revenue during 2025 and a growing subscription base, VINIA's performance highlights the effectiveness of BioHarvest's innovative technology. Overall, VINIA's success underscores the increasing consumer recognition and adoption of its health benefits.
Read more →-BHST
Mar 17, 2026DATED MARCH 17, 2026 News Release dated
BioHarvest Sciences Inc. has announced that it will report its fourth quarter and full year financial results for 2025 on March 31, 2026. The announcement includes details for a conference call and webcast to discuss the results and the company's business operations. These results are anticipated following the company's continued development in its Botanical Synthesis platform, indicating its focus on both transparency and innovation in the market.
Read more →-BHST
Mar 13, 2026DATED MARCH 13, 2026 News Release dated
BioHarvest Sciences has announced the approval of long-term incentive awards for its employees, officers, and directors, designed to align the interests of the team with shareholders. The grants comprise 516,812 stock options and 264,121 restricted share units, which will vest quarterly over three years. This initiative aims to support the company's growth and innovation while maintaining cash management discipline. However, the company acknowledges potential risks associated with retaining key personnel and external uncertainties affecting its value.
Read more →-BHST
Mar 6, 2026MATERIAL CHANGE REPORT DATED MARCH 6, 2026 Material Change Report dated
BioHarvest Sciences Inc. reported a change in its board of directors, with David Tsur resigning and Prof. Hezi Levy appointed as his replacement. Prof. Levy brings extensive experience, having previously served as Director General of the Israeli Ministry of Health and led major health initiatives during the COVID-19 pandemic. His appointment is seen as a strategic move to bolster the company's leadership with robust healthcare expertise.
Read more →-BHST
Mar 5, 2026BioHarvest Sciences Announces Board Transition and Appointment of Prof. Hezi Levy
BioHarvest Sciences has announced a transition in its board, appointing Prof. Hezi Levy as a new member. This strategic move is intended to strengthen the company's governance and direction. Prof. Levy's extensive experience is anticipated to contribute positively to the company's future growth.
Read more →-BHST
Mar 5, 2026BioHarvest Sciences Announces Board Transition and Appointment of Prof.
BioHarvest Sciences Inc. announced a leadership change with Mr. David Tsur stepping down from the Board of Directors after four years, effective immediately. Prof. Hezi Levy has been appointed to the Board, bringing decades of experience in healthcare leadership, notably during his tenure as Director General of the Israeli Ministry of Health. The Chairman expressed gratitude for Mr. Tsur's contributions and highlighted the significance of Prof. Levy's expertise in strengthening the company's governance and growth initiatives.
Read more →-BHST
Mar 3, 2026DATED MARCH 3, 2026 News Release dated
BioHarvest Sciences Inc. will participate in the 38th Annual Roth Conference from March 22-24, 2026, in Dana Point, California. CEO Ilan Sobel will meet with institutional investors to discuss the company's strategic direction and growth prospects, following a successful financing round in Q4 2025. With over 85,000 direct customers and a focus on plant-based compounds, BioHarvest aims to achieve significant milestones in 2026 through both its contract development and manufacturing operations and new wellness products.
Read more →-BHST
Jan 7, 2026BioHarvest Sciences Issues Year End Shareholder Letter
BioHarvest Sciences issued its year-end shareholder letter, highlighting a significant first year as a NASDAQ-listed company with an annualized revenue run rate above $36 million and gross margins exceeding 60%. The company plans aggressive growth in its D2C products, led by the VINIA brand, and reports positive consumer feedback on new offerings. Its CDMO Services division is onboarding major collaborative contracts and anticipates that future revenues will surpass its products division. With a strengthened balance sheet and expanded capabilities, BioHarvest is committed to accelerating growth and achieving adjusted EBITDA breakeven in the near future.
Read more →-BHST
Dec 18, 2025DATED DECEMBER 18, 2025 News Release dated
BioHarvest Sciences has been awarded a $1.6 million grant from the Israeli Innovation Authority to enhance its second-generation Botanical Synthesis platform. This funding is designed to advance the company's capabilities in artificial intelligence, manufacturing efficiency, and production scalability. The grant is non-dilutive and will further support BioHarvest's strategic plans without impacting shareholder equity. CEO Ilan Sobel highlighted the grant as a validation of the company's technology leadership.
Read more →-BHST
Dec 3, 2025BIOHARVEST SCIENCES ANNOUNCES LAUNCH OF VINIA BLOOD FLOW HYDRATION PRODUCT
BioHarvest Sciences has launched VINIA Blood Flow Hydration, the first hydration product utilizing VINIA's blood flow enhancing Piceid Resveratrol, in the U.S. This innovative solution aims to improve the delivery of fluids and electrolytes in a growing market worth $13 billion. The product has garnered positive responses from early adopters and is backed by a 90-day guarantee. BioHarvest aims to disrupt the hydration market by combining effective hydration with enhanced blood flow.
Read more →-BHST
Nov 13, 2025UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Unaudited Interim Condensed Consolidated Financial Statements BioHarvest Sciences Inc. Unaudited Interim Condensed Consolidated Financial Statements For the T
BioHarvest Sciences Inc. released its unaudited interim condensed consolidated financial statements for the three and nine months ended September 30, 2025. The company reported a significant increase in total assets to $35,188, representing a growth from $25,001 in the previous year. Despite higher revenues of $25,442, the net loss for the period was reported at $8,931, which, while improved from previous year losses, indicates ongoing financial challenges. Overall, the results show a mixture of growth opportunities amid persistent operating losses and accrued liabilities.
Read more →-BHST
Nov 12, 2025DATED NOVEMBER 12, 2025 News Release dated
BioHarvest Sciences Inc. announced its attendance at the Craig-Hallum 16th Annual Alpha Select Conference on November 18, 2025, in New York, NY. CEO Ilan Sobel will conduct one-on-one meetings with institutional investors during the event. The company is experiencing strong momentum in its consumer and contract development platform, driven by robust sales in its VINIA capsule business and new product offerings. BioHarvest’s recent successful equity offering indicates a focus on achieving profitability and sustainable growth.
Read more →-BHST
Nov 10, 2025DATED NOVEMBER 10, 2025 News Release dated
BioHarvest Sciences Inc. has successfully completed an underwritten public offering, raising $19.9 million by issuing 2,846,854 shares at a price of $7.00 each. The proceeds are aimed at funding various initiatives, including manufacturing expansion, research and development, and working capital. The offering was well-received and resulted in the inclusion of new U.S. institutional investors in the company's shareholder base. CEO Ilan Sobel expressed optimism about the capital raise and its potential to accelerate company growth.
Read more →-BHST
Nov 7, 2025MATERIAL CHANGE REPORT Material Change Report FORM 51-102F3 MATERIAL CHANGE REPORT Item 1 . Name and Address of Company BIOHARVEST SCIENCES INC. Suite 1140 - 625 Howe Street Vancouver, BC, V6C 2T6 (the "Company" or "BioH
BioHarvest Sciences Inc. has announced its intention to conduct an underwritten public offering of 2,485,000 shares of common stock at a price of $7.00 per share. The offering is expected to generate approximately $17.4 million in gross proceeds, which will be utilized for various corporate purposes, including research and development and debt refinancing. The company has granted underwriters a 30-day option to purchase additional shares, and the offering is anticipated to close around November 10, 2025, subject to customary conditions.
Read more →-BHST
Nov 4, 2025BioHarvest Sciences to Host Third Quarter Earnings Call on November 13 at 4:30 p.m.
BioHarvest Sciences Inc. has announced it will hold a third quarter earnings call on November 13, 2025, at 4:30 p.m. Eastern Time. The call will discuss the financial results for the quarter ending September 30, 2025, and also provide a corporate update. Participants will have the opportunity to engage in a question-and-answer session. This call demonstrates the company's commitment to financial transparency and investor communication.
Read more →-BHST
Oct 31, 2025MATERIAL CHANGE REPORT DATED OCTOBER 31, 2025 Material Change Report dated
BioHarvest Sciences Inc. has announced a strategic CDMO agreement with Saffron Tech Ltd. to develop saffron-derived botanical compounds using its patented Botanical Synthesis platform. This collaboration aims to provide a sustainable production alternative to traditional saffron cultivation methods, which are hindered by climate change and various regional instabilities. The partnership plans to manufacture large-scale products for BioHarvest's e-commerce platform, focusing on the nutraceutical benefits of saffron. Notably, Saffron Tech holds 75% ownership of the developed compositions under this agreement.
Read more →-BHST
Oct 30, 2025DATED OCTOBER 30, 2025 News Release dated
BioHarvest Sciences Inc. announced a strategic CDMO partnership with Saffron Tech to enhance saffron compound production through its Botanical Synthesis platform. This collaboration aims to address the challenges associated with traditional saffron cultivation, such as high costs and seasonal volatility. BioHarvest anticipates revenue growth and product launches in the forthcoming fourth quarter of 2025, despite preliminary EBITDA losses. Saffron Tech will retain a significant share of the generated IP and compositions under the agreement.
Read more →-BHST
Sep 22, 2025MATERIAL CHANGE REPORT DATED SEPTEMBER 23, 2025 Material Change Report dated September 23,, 2025 FORM 51-102F3 MATERIAL CHANGE REPORT Item 1. Name and Address of Company BIOHARVEST SCIENCES INC. Suite 1140 - 625 Howe Str
BioHarvest Sciences Inc. announced in a material change report that it successfully completed warrant exercises and debt conversions totaling $10.9 million and $3.8 million, respectively. These transactions, aimed at enhancing the company's financial stability, include raising funds through the exercising of warrants and converting convertible notes into shares. The company is using the proceeds for capital expenditures, refinancing remaining debt, and working capital. Following these changes, BioHarvest's total debt is approximately $6.6 million.
Read more →-BHST
Sep 22, 2025DATED SEPTEMBER 22, 2025 News Release dated
BioHarvest Sciences Inc. has successfully completed a series of transactions to strengthen its balance sheet, raising $10.9 million in gross proceeds and reducing total debt by $3.8 million. The transactions included raising cash through the exercise of warrants and the conversion of debt to equity, designed to provide financial flexibility for future growth. CEO Ilan Sobel highlighted this as a pivotal milestone, enhancing their capacity for capital expenditures and working capital. The company aims to accelerate its initiatives across its product and CDMO services divisions.
Read more →-BHST
Sep 10, 2025DATED SEPTEMBER 10, 2025 News Release dated
BioHarvest Sciences Inc. announced a major advancement in its Botanical Synthesis technology by successfully producing plant-based exosomes at scale. This development allows the company to explore new revenue opportunities within cosmetic and health sectors. The exosomes enhance the delivery of viniferin, a sought-after compound in skincare applications, and position BioHarvest to enter a growing market expected to reach $2.2 billion by 2030. The CEO expressed optimism about launching a differentiated skincare application within the next 18 to 24 months, leveraging the advanced absorption features of these exosomes.
Read more →-BHST
Sep 9, 2025BIOHARVEST SCIENCES INC.
BioHarvest Sciences Inc. has announced the effectiveness of its shelf registration statement on Form F-3 with the SEC. This allows the company to offer and sell up to $100 million in common shares, warrants, and units as needed depending on market conditions and capital requirements. Importantly, the registration does not obligate the company to sell any specific amount, maintaining flexibility. The move is intended to enhance the company's liquidity and support future initiatives, although it introduces variability based on market dynamics.
Read more →-BHST
Sep 8, 2025MATERIAL CHANGE REPORT DATED SEPTEMBER 9 , 2025 Material Change Report dated September 9 , 2025 FORM 51-102F3 MATERIAL CHANGE REPORT Item 1. Name and Address of Company BIOHARVEST SCIENCES INC. Suite 1140 - 625 Howe Stre
BioHarvest Sciences Inc. has announced the filing and effectiveness of a shelf registration statement on Form F-3 with the U.S. Securities and Exchange Commission. This registration allows the company to offer and sell up to USD $100 million of its securities, which includes common shares and warrants, depending on market conditions and capital needs. The company emphasizes that this registration does not guarantee any specific amount will be sold and remains at its discretion based on the market environment.
Read more →-BHST
Sep 2, 2025DATED SEPTEMBER 2, 2025 News Release dated
BioHarvest Sciences Inc. will host a virtual investor webinar on September 10, 2025, led by CEO Ilan Sobel. The event will cover corporate updates, including new capability-building initiatives and the company's strategic goals for the second half of 2025. Participants will have the opportunity to engage in a question-and-answer session following the presentation. This webinar highlights BioHarvest's commitment to transparency and its focus on driving profitable growth in the nutraceutical and contract development sectors.
Read more →-BHST
Aug 14, 2025MATERIAL CHANGE REPORT DATED AUGUST 14, 2025 Material Change Report dated
BioHarvest Sciences Inc. has updated its insider trading policy, as announced by the board of directors. The new policy establishes a revised trading window that begins two trading days after the public release of quarterly or year-end results, lasting until 15 days before the due date for those results. This change aims to establish a more reasonable timeframe for trading activities related to the company's financial disclosures. Further details can be obtained through the company's investor relations contact.
Read more →-BHST
Aug 13, 2025BioHarvest Sciences Amended Insider Trading Policy
BioHarvest Sciences Inc. has announced an amended insider trading policy, aimed at establishing a more reasonable trading window for its shareholders. The new trading window will open after two full trading days following the public release of quarterly or year-end results and will close 15 days prior to the due date for these results. This change is expected to promote transparency and align trading practices more closely with publicly available information. BioHarvest continues to leverage its patented Botanical Synthesis technology for developing innovative plant-based solutions.
Read more →-BHST
Aug 11, 2025DATED AUGUST 11, 2025 News Release dated
BioHarvest Sciences Inc. reported a robust 41% increase in revenues for the second quarter of 2025, reaching $8.5 million, largely driven by their core capsule business and new product launches. The company also validated its botanical synthesis platform through the successful completion of a Stage 1 development contract with a pharmaceutical company. Despite revenue growth, a net loss of $4 million was reported, and management highlighted rising operating expenses. Looking ahead, BioHarvest plans to launch multiple initiatives to enhance growth and reach adjusted EBITDA breakeven by the end of 2025.
Read more →-BHST
Aug 5, 2025BioHarvest Sciences to Host Second Quarter 2025 Earnings Call on August 11 at 8:00 a.m.
BioHarvest Sciences Inc. has announced an upcoming earnings call scheduled for August 11, 2025, at 8:00 a.m. Eastern Time to discuss its financial results for the second quarter of 2025. The call will provide an overview of the company's performance and a corporate update, concluding with a question-and-answer session for participants. This event highlights BioHarvest's commitment to transparency and investor communication.
Read more →-BHST
Jul 23, 2025DATED JULY 23, 2025 News Release dated
BioHarvest Sciences Inc. has announced its upcoming presentation at the Canaccord Genuity 45th Annual Growth Conference scheduled for August 12-14, 2025, in Boston. CEO Ilan Sobel will engage in one-on-one meetings with institutional investors and deliver a corporate presentation outlining the company's growth plans. The firm highlights its patented Botanical Synthesis technology and its dual business verticals in nutraceutical products and contract development. This event is seen as an opportunity to solidify investor confidence and showcase ongoing momentum in its operations.
Read more →-BHST
Jul 4, 2025MATERIAL CHANGE REPORT DATED JULY 4, 2025 Material Change Report dated
BioHarvest Sciences Inc. announced the outcomes of its annual general meeting held on June 26, 2025. Shareholders approved all proposed motions, including the election of directors and the establishment of a new Equity Incentive Compensation Plan. The company's articles were also amended to implement a staggered board, intended to provide greater board continuity. Auditors for the company were appointed, further solidifying governance structures.
Read more →-BHST
Jul 3, 2025Rehovot, Israel - July 2, 2025 - BioHarvest Sciences Inc.
BioHarvest Sciences Inc. held its annual general and special meeting on June 26, 2025, where shareholders approved all proposed motions, including changes to the board structure. The new board will be divided into three classes with staggered terms, allowing for a more organized governance approach. Additionally, shareholders elected six directors and confirmed the appointment of Ziv Haft as the company's auditors. The meeting also validated the company's Equity Incentive Compensation Plan.
Read more →-BHST
Jun 10, 2025TO ALL APPLICABLE REGULATORS AND EXCHANGES
BioHarvest Sciences Inc. has announced details for its upcoming Annual General & Special Meeting of Security Holders. The meeting is scheduled to take place on June 26, 2025, in Vancouver, BC, with a record date for notice and voting set for May 20, 2025. The announcement includes specifics regarding the securities involved and the procedures for beneficial ownership determination.
Read more →-BHST
Jun 4, 2025DATED JUNE 4, 2025 News Release dated
BioHarvest Sciences Inc. has launched VINIA DailyChews 2X Formula, a chewable product aimed at enhancing nitric oxide production and blood flow for athletes and active individuals. Certified by Informed Sport, this product ensures safety by being tested for banned substances, making it appealing to professional athletes and fitness enthusiasts. This launch not only enlarges BioHarvest's product line but also positions the company within the growing nutraceutical market. Additionally, the new ecommerce platform facilitates international sales, thereby broadening customer reach.
Read more →-BHST
May 21, 2025DATED MAY 21, 2025 News Release dated
BioHarvest Sciences Inc. has announced a new contract for its Botanical Synthesis CDMO Services to develop a plant-based fragrance compound. This venture marks the company's entry into the multi-billion-dollar fragrance market, leveraging AI technology to select the optimal plant species for production. The agreement includes milestone payments and emphasizes the need for further development stages to achieve commercial viability. While this contract represents growth potential, certain uncertainties regarding future contracts and market acceptance remain.
Read more →-BHST
May 15, 2025DATED MAY 15, 2025 News Release dated
BioHarvest Sciences Inc. reported financial results for the first quarter of 2025, highlighting a 47% increase in revenues to $7.9 million, surpassing management guidance. The company also noted a growing subscriber base for its VINIA product, exceeding 50,000. However, despite the revenue growth, BioHarvest reported a net loss of $2.3 million for the quarter, signaling ongoing financial challenges that the company aims to address with upcoming product launches and strategies in its CDMO division.
Read more →-BHST
May 12, 2025DATED MAY 12, 2025 News Release dated
BioHarvest Sciences Inc. announced the successful transition of its contract development and manufacturing organization (CDMO) project from Stage 1 to Stage 2. This achievement validates their Botanical Synthesis technology, which isolates and multiplies plant cells for pharmaceutical use. Stage 1 focused on sourcing plants for compound development, while Stage 2 will test biomass suitability and optimize growing conditions. The company's leadership expressed optimism about future opportunities and the validated capabilities of their in-house AI tools.
Read more →-BHST
May 1, 2025DATED MAY 1, 2025 News Release dated
BioHarvest Sciences Inc. will announce its first quarter 2025 financial results on May 15, 2025, after market close. Following the release, management will host a conference call to discuss the results and provide a corporate update. The call is scheduled for 4:30 p.m. Eastern Time and will include a question-and-answer session for participants. The company's innovative Botanical Synthesis technology positions it within the nutraceutical market as it develops various health and wellness products.
Read more →-BHST
Apr 1, 2025CERTIFICATION OF ANNUAL FILINGS - CEO Certification of Annual Filings - CEO Form 52-109F1 Certification of Annual Filings Full Certificate I, Ilan Sobel, the Chief Executive Officer of BioHarvest Sciences Inc. , certify
Ilan Sobel, CEO of BioHarvest Sciences Inc., has certified the annual filings for the financial year ending December 31, 2024. He confirmed that the filings do not contain any misleading statements and that the financial statements accurately represent the company's financial status. Additionally, he stated that the company has established adequate internal controls for disclosure and reporting. The certification indicates a commitment to transparency and accuracy in financial reporting.
Read more →-BHST
Mar 31, 2025DATED MARCH 31, 2025 News Release dated
BioHarvest Sciences Inc. reported robust financial results for Q4 and full year 2024, with revenues increasing significantly alongside operational enhancements. The Company announced a key partnership with Tate & Lyle, aiming to develop innovative plant-based sweeteners, thereby expanding its market reach. Management forecasts positive trends with expectations of reaching EBITDA breakeven in the latter half of 2025, despite a net loss in the fourth quarter. Additionally, BioHarvest continues to grow its VINIA product lines, which have seen increased subscriber engagement and sales.
Read more →-BHST
Mar 17, 2025DATED MARCH 17, 2025 Press Release dated
BioHarvest Sciences Inc. will host an earnings call on March 31, 2025, to discuss its financial results for the fourth quarter and full year ended December 31, 2024. The call will provide corporate updates along with a Q&A session, showcasing the company's commitment to engaging with investors. This event reflects BioHarvest's ongoing operations and financial transparency as a leader in Botanical Synthesis technology.
Read more →-BHST
Mar 6, 2025DATED MARCH 6, 2025 Press Release dated
BioHarvest Sciences Inc. has announced its participation in the 37th Annual Roth Conference from March 16-18, 2025. CEO Ilan Sobel will engage in one-on-one meetings with institutional investors to showcase the company's growth prospects. BioHarvest highlights significant achievements, including a $50 Million cumulative sales milestone for its product VINIA and the recent launch of its CDMO Services Division. The event presents an opportunity for the company to promote its innovative Botanical Synthesis technology.
Read more →-BHST
Mar 4, 2025DATED MARCH 4, 2025 Press Release dated
BioHarvest Sciences Inc. has reported promising results from in vitro tests of its proprietary Olive Cell compound, which reduces fat accumulation in liver cells. This aims to address Non-Alcoholic Fatty Liver Disease (NAFLD), impacting a significant portion of U.S. adults. The company plans to market the Olive Cell product as a nutraceutical in 2026 and explores partnerships for pharmaceutical applications. While the results are optimistic, challenges remain regarding regulatory approval and market acceptance.
Read more →-BHST
Feb 18, 2025DATED FEBRUARY 18, 2025 Press Release dated
BioHarvest Sciences Inc. has announced that its flagship product, VINIA, has surpassed $50 million in cumulative sales within less than four years of its launch in the U.S. The supplement, derived from a patented Botanical Synthesis technology, boasts over 50,000 active users and a high customer satisfaction rating. The company is also planning to quadruple production capacity with a new facility by late 2026. However, there are inherent risks associated with the expansion and future product development.
Read more →-BHST
Feb 14, 2025MATERIAL CHANGE REPORT DATED FEBRUARY 14, 2025 Material Change Report dated
BioHarvest Sciences Inc. announced its voluntary delisting from the Canadian Securities Exchange (CSE), effective February 14, 2025. The company has received approval for this action, believing that the current trading volume on the CSE does not justify the costs associated with maintaining a dual listing. BioHarvest will continue to trade on the Nasdaq Global Market under the symbol 'BHST'. The management anticipates that this consolidation will improve liquidity and shareholder value.
Read more →-BHST
Feb 12, 2025DATED FEBRUARY 12, 2025 News Release dated
BioHarvest Sciences Inc. has announced its participation in the WeBull Consumer Stocks Virtual Webinar scheduled for February 18, 2025. The company's CEO, Ilan Sobel, will present their patented Botanical Synthesis technology and its implications for multiple industries, including nutraceuticals and pharmaceuticals. Following the live event, a replay of the presentation will be available on the company's investor relations website. The information shared is expected to focus on the growth of BioHarvest's direct-to-consumer business and its upcoming opportunities in contract development and production services.
Read more →-BHST
Feb 10, 2025DATED FEBRUARY 10, 2025 Press Release dated
BioHarvest Sciences has announced its voluntary delisting from the Canadian Securities Exchange (CSE) after receiving approval. The company plans to streamline trading by focusing solely on its Nasdaq listing, which is anticipated to boost liquidity and shareholder value. The last trading day on the CSE is expected to be February 14, 2025. BioHarvest continues to operate in the field of Botanical Synthesis, enhancing its market presence through Nasdaq.
Read more →-BHST
Jan 23, 2025Item 1.Name and Address of Company
BioHarvest Sciences Inc. announced the appointment of Sharon Malka as an independent director. With over 25 years of experience in technology and capital markets, Malka's expertise is expected to contribute significantly to the company's growth. His operational background is well-aligned with BioHarvest's focus on developing cutting-edge therapeutic solutions through its Botanical Synthesis technology. The appointment aims to enhance the company's strategy as it progresses through a transformative phase.
Read more →-BHST
Jan 8, 2025DATED JANUARY 8, 2025 News Release dated
BioHarvest Sciences Inc. announced a transformative year in 2024, highlighting growth in their core VINIA capsule business and the launch of a new CDMO Services division. The company forged a significant partnership with Tate & Lyle and is set to expand its product offerings to engage a wider consumer base. Additionally, a successful Nasdaq uplisting aims to boost visibility and attract U.S. investors. With strategic investments in infrastructure and technology, BioHarvest anticipates continued revenue growth and operational success in 2025.
Read more →-BHST
Dec 11, 2024____________________________________________________________________________
Tate & Lyle and BioHarvest Sciences have formed a partnership to develop innovative plant-based ingredients using BioHarvest's Botanical Synthesis technology. The collaboration aims to create affordable and sustainable botanical sweeteners that align with consumer preferences for healthier food and beverage options. This partnership blends Tate & Lyle's extensive experience in ingredient solutions with BioHarvest's unique production capabilities. While the collaboration is promising, the commercialization and product suitability testing of the new sweeteners remain challenges.
Read more →-BHST
Nov 25, 2024BioHarvest Launches VINIA SuperFood Functional Tea Line
BioHarvest Sciences has announced the launch of its VINIA SuperFood functional tea line, featuring blends such as Black Tea, Green Tea, and Matcha Green Tea. This product aims to capture a share of the $3.3 billion North American functional tea market. The teas are infused with piceid resveratrol, mirroring the benefits of the existing VINIA supplements. The CEO emphasized the new line's potential to meet demand among younger consumers and its superiority in taste and efficacy compared to established brands.
Read more →-BHST
Nov 25, 2024DATED NOVEMBER 25, 2024 News Release dated
BioHarvest Sciences reported a significant revenue increase of 101% year-over-year, reaching over $6.5 million for Q3 2024. The company's gross margins improved notably to 57% due to better manufacturing efficiencies. However, despite this growth, BioHarvest incurred a net loss of $2.7 million, reflecting increased operating expenses. The launch of new product lines and a substantial rise in VINIA subscribers indicate a robust business trajectory, despite challenges such as higher costs from geopolitical events.
Read more →-BHST
Nov 21, 2024DATED NOVEMBER 21, 2024 News Release dated
BioHarvest Sciences Inc. announced its participation in the Noble Capital Markets 20th Annual Emerging Growth Equity Conference scheduled for December 3, 2024, in Boca Raton, FL. CEO Ilan Sobel will engage with institutional investors and present the company's growth strategies. Following its recent Nasdaq listing, BioHarvest has received positive feedback, and the company aims to discuss advancements in commercializing plant-based molecules. A link to the presentation will be made available afterward on their investor relations website.
Read more →-BHST
Nov 18, 2024DATED NOVEMBER 18, 2024 News Release dated
BioHarvest Sciences Inc. has announced that it will release its third quarter 2024 financial results on November 25, 2024. The company will host an investor conference call to discuss these results and provide a corporate update. BioHarvest is known for its patented Botanical Synthesis technology, which allows for the production of plant-based molecules without the need to grow the actual plants. This call is an opportunity for investors to engage directly with the management team.
Read more →-BHST
Nov 18, 2024VANCOUVER, CANADA, and REHOVOT, ISRAEL, November 15, 2024 - BioHarvest Sciences Inc.
BioHarvest Sciences Inc. has granted 5,400 Restricted Share Units and 111,998 stock options to employees and consultants, with a deemed issuance price of CAD $8.48 per share. The RSUs will vest after 12 months, while the stock options have various vesting terms extending up to 3 years. The company specializes in botanical synthesis aimed at creating therapeutic solutions and nutraceutical products. However, it has warned investors about the uncertainties surrounding future growth and profitability.
Read more →-BHST
Nov 12, 2024DATED NOVEMBER 12, 2024 News Release dated
BioHarvest Sciences Inc. has announced that its shares will begin trading on the Nasdaq Global Market under the ticker symbol 'BHST'. This milestone is seen as a significant step in increasing the company's visibility and liquidity while broadening its potential shareholder base. The company is also set to release its third quarter financial results on November 25, 2024, and will host an investor conference call to discuss these results. BioHarvest uses its patented Botanical Synthesis technology for developing therapeutic solutions and nutraceutical products.
Read more →-BHST
Nov 7, 2024DATED NOVEMBER 7, 2024 News Release dated
BioHarvest Sciences Inc. announced its uplisting to the Nasdaq Global Market, with trading set to begin on November 12, 2024, under the ticker 'BHST'. This approval marks a significant milestone for the company and is expected to improve shareholder access and liquidity. The leadership expressed pride in the operational achievements that have led to this listing, aiming to expand their global shareholder base effectively. The company will continue to trade on the OTCQB until the transition is complete.
Read more →-BHST
Oct 23, 2024BioHarvest Sciences Announces Record Preliminary Third Quarter 2024 Financial Results
BioHarvest Sciences Inc. announced record preliminary financial results for Q3 2024, with revenue expected to reach at least $6.5 million, marking a significant increase of 100% from the previous year. The company has also provided guidance for Q4 2024 revenues, predicting they could grow to at least $7.2 million. Moreover, BioHarvest is nearing completion of its Nasdaq listing application, intending to uplist by year-end, which could provide further market opportunities. However, the company anticipates net losses for the quarter, reflecting ongoing financial pressures alongside its growth plans.
Read more →-BHST
Oct 16, 2024DATED OCTOBER 16, 2024 News Release dated
BioHarvest Sciences Inc. announced its participation in the LD Micro Main Event XVII Conference on October 30, 2024, in Los Angeles. CEO Ilan Sobel will conduct one-on-one meetings with institutional investors and present virtually. He expressed optimism about the company's steady growth and plans to introduce new products in the fourth quarter of 2024, aiming for a Nasdaq listing by year-end. The event underscores BioHarvest's commitment to engaging with investors and showcasing its innovative Botanical Synthesis technology.
Read more →-BHST
Sep 20, 2024MATERIAL CHANGE REPORT DATED SEPTEMBER 20, 2024 Material Change Report dated
BioHarvest Sciences Inc. announced the resignation of David Ryan from its board of directors as part of a strategy to comply with Nasdaq's requirement for a majority of independent directors. Despite resigning from the board, Ryan will retain his position as Vice President of Investor Relations. This internal shift aims to improve the company's governance structure as it prepares for a potential listing on the Nasdaq Stock Market.
Read more →-BHST
Sep 20, 2024Vancouver, British Columbia and Rehovot, Israel - September 20, 2024 - BioHarvest Sciences Inc.
BioHarvest Sciences Inc. announced the resignation of David Ryan as a director to comply with Nasdaq requirements for independent directors. Ryan will continue to serve as Vice President of Investor Relations. The Board expressed gratitude for his founding contributions to the company. This strategic move supports BioHarvest's plans to apply for a listing on the Nasdaq Stock Market, reflecting its growth intentions.
Read more →-BHST
Sep 12, 2024DATED SEPTEMBER 12, 2024 Press Release dated
BioHarvest Sciences Inc. has been invited to present at the iAccess Alpha Buyside Best Ideas Conference, scheduled for September 24-25, 2024. CEO Ilan Sobel will host virtual one-on-one meetings with institutional investors and a public presentation. This event marks an opportunity for the company to showcase its patented Botanical Synthesis technology to potential investors. All interested parties can participate via an online webcast, with the aim of fostering investor relations and increasing visibility in the market.
Read more →-BHST
Sep 5, 2024MONTHLY PROGRESS REPORT DATED SEPTEMBER 5, 2024 Monthly Progress Report dated
BioHarvest Sciences Inc. (BHSC) released its monthly progress report reflecting strong performance in August 2024. The company reported a 119% revenue increase, driven by significant subscriber growth for its VINIA product line. Ongoing expansion plans include a new manufacturing facility and a variety of new product developments aimed at enhancing market presence. However, the company still faces net losses and operational challenges attributed to geopolitical events in Israel.
Read more →-BHST
Sep 4, 2024DATED SEPTEMBER 4, 2024 News Release Dated
BioHarvest Sciences Inc. will participate in the upcoming H.C. Wainwright 26th Annual Global Investment Conference on September 9-10, 2024, in New York City. CEO Ilan Sobel will conduct one-on-one meetings with institutional investors and deliver a presentation that can be streamed live. This conference represents a significant opportunity for BioHarvest to showcase its patented Botanical Synthesis technology platform and engage directly with potential investors.
Read more →-BHST
Aug 29, 2024BioHarvest Sciences Surpasses USD $1.0 Million in Cumulative Direct Sales of Coffee with VINIA Inside
BioHarvest Sciences Inc. announced that its VINIA Superfood Coffee product line has surpassed USD $1.0 million in cumulative direct sales since its launch in December 2023. The product line, which incorporates the VINIA Red Grape Superfood into coffee pods, has received positive customer feedback, scoring 4.8 out of 5 in ratings. Additionally, taste tests showed consumer preference over leading competitors. CEO Ilan Sobel indicated that this success validates the company's strategy in the functional coffee market, with plans to expand by introducing new compatible pods.
Read more →Competitive Position
How BHST ranks across every disease it competes inCompetitive Position is a premium feature
See how BHST ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial